₩20,400.00 ($15.19)

+300.00 (+1.49%)

Weekly Expected Move ±3.4%

₩18995 ₩19698 ₩20400 ₩21102 ₩21805

KSC · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Sell · Power 29 · ₩227.2B mcap · 4M float · 1.00% daily turnover

Revenue

$722.3B +10.6% ▲

5Y CAGR: +5.5%

Gross Profit

$123.3B +19.5% ▲

5Y CAGR: +0.4%

Operating Income

$50.2B +48.3% ▲

5Y CAGR: -7.5%

Net Income

$43.5B +138.0% ▲

5Y CAGR: -3.9%

EPS (Diluted)

$3910.89 +138.0% ▲

5Y CAGR: -3.9%

EBITDA

$91.2B +24.2% ▲

5Y CAGR: -3.7%

View Full Income Statement

Line Item	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$596.7B	$635.0B	$594.6B	$653.3B	$722.3B
YoY Growth	+7.9%	+6.4%	-6.4%	+9.9%	+10.6%
Cost of Revenue	$470.5B	$497.7B	$495.5B	$550.0B	$599.0B
Gross Profit	$126.2B	$137.3B	$99.0B	$103.2B	$123.3B
Gross Margin	21.2%	21.6%	16.7%	15.8%	17.1%
R&D Expenses	$7.1B	$7.4B	$7.0B	$7.9B	$0
SG&A Expenses	$29.5B	$41.5B	$26.2B	$27.0B	$0
Operating Expenses	$56.6B	$75.3B	$56.0B	$69.4B	$72.6B
Operating Income	$69.6B	$62.0B	$43.0B	$33.8B	$50.2B
Operating Margin	11.7%	9.8%	7.2%	5.2%	7.0%
Interest Expense	$7.7B	$11.2B	$19.7B	$21.0B	$17.6B
Income Before Tax	$74.8B	$51.9B	$14.0B	$31.2B	$53.8B
Tax Expense	$15.6B	$11.3B	$5.1B	$9.7B	$6.6B
Net Income	$53.7B	$34.0B	$6.1B	$18.3B	$43.5B
Net Margin	9.0%	5.4%	1.0%	2.8%	6.0%
EPS (Diluted)	$4828.54	$3056.41	$550.33	$1643.12	$3910.89
EBITDA	$114.9B	$98.6B	$77.0B	$73.5B	$91.2B
Shares Outstanding	11M	11M	11M	11M	12M

Line Item	FY2024 Q3	FY2024 Q4	FY2025 Q1	FY2025 Q2	FY2025 Q3	FY2025 Q4	FY2026 Q1	FY2026 Q2
Revenue	$166.6B	$148.6B	$180.8B	$190.0B	$185.0B	$166.4B	$201.6B	$212.9B
Cost of Revenue	$141.7B	$125.7B	$153.0B	$152.0B	$151.0B	$143.1B	$165.3B	$171.9B
Gross Profit	$24.9B	$22.9B	$27.8B	$38.0B	$34.1B	$23.3B	$36.2B	$41.0B
Gross Margin	14.9%	15.4%	15.4%	20.0%	18.4%	14.0%	18.0%	19.3%
R&D Expenses	$2.1B	$2.2B	$0	$2.6B	$2.3B	$2.7B	$1.9B	$2.4B
SG&A Expenses	$6.8B	$5.9B	$16.3B	$7.9B	$10.3B	$10.8B	$7.7B	$7.9B
Operating Expenses	$17.5B	$19.5B	$16.3B	$17.9B	$20.4B	$23.0B	$15.0B	$18.6B
Operating Income	$7.4B	$3.4B	$11.6B	$20.1B	$13.7B	$4.9B	$21.2B	$22.4B
Operating Margin	4.5%	2.3%	6.4%	10.6%	7.4%	3.0%	10.5%	10.5%
Interest Expense	$5.3B	$5.2B	$4.7B	$4.5B	$4.5B	$4.1B	$4.0B	$4.0B
Income Before Tax	$13.5B	$1.3B	$9.1B	$25.1B	$13.6B	$5.9B	$19.9B	$21.7B
Tax Expense	$2.9B	-$114M	$2.5B	$1.1B	$3.2B	-$221M	$5.4B	$5.2B
Net Income	$10.6B	$619M	$5.9B	$23.9B	$9.0B	$4.6B	$11.8B	$13.7B
Net Margin	6.4%	0.4%	3.3%	12.6%	4.9%	2.8%	5.9%	6.4%
EPS (Diluted)	$957.00	$55.62	$533.06	$2153.00	$808.00	$416.83	$1060.78	$1231.21
EBITDA	$28.8B	$17.0B	$38.4B	$39.3B	$27.9B	-$14.4B	$31.7B	$33.4B
Shares Outstanding	11M	11M	11M	11M	11M	9M	11M	11M

008490.KS KSC